GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (TSX:TLRY) » Definitions » COGS-to-Revenue

Tilray Brands (TSX:TLRY) COGS-to-Revenue : 0.74 (As of Feb. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Tilray Brands COGS-to-Revenue?

Tilray Brands's Cost of Goods Sold for the three months ended in Feb. 2024 was C$188 Mil. Its Revenue for the three months ended in Feb. 2024 was C$254 Mil.

Tilray Brands's COGS to Revenue for the three months ended in Feb. 2024 was 0.74.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Tilray Brands's Gross Margin % for the three months ended in Feb. 2024 was 26.23%.


Tilray Brands COGS-to-Revenue Historical Data

The historical data trend for Tilray Brands's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands COGS-to-Revenue Chart

Tilray Brands Annual Data
Trend Aug14 May15 May16 May17 May18 May19 May20 May21 May22 May23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.76 0.76 0.81 0.77

Tilray Brands Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 0.64 0.75 0.76 0.74

Tilray Brands COGS-to-Revenue Calculation

Tilray Brands's COGS to Revenue for the fiscal year that ended in May. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=649.038 / 847.684
=0.77

Tilray Brands's COGS to Revenue for the quarter that ended in Feb. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=187.574 / 254.259
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tilray Brands  (TSX:TLRY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Tilray Brands's Gross Margin % for the three months ended in Feb. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 187.574 / 254.259
=26.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Tilray Brands COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tilray Brands's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands (TSX:TLRY) Business Description

Traded in Other Exchanges
Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.